 The purpose of this study is to determine the efficacy of the combined therapy Bevacizumab, trastuzumab and paclitaxel in neo-adjuvant therapy in patients with breast cancer HER 2 followed by surgery and adjuvant therapy Cyclophosphamide, Trastuzumab and Doxorubicin liposomal. 